Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1800 results
December 2016
-
Media ReleaseNovartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSCIf approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)[1] Seizures are the most…
-
Media ReleaseNovartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group LimitedAcquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline Investigational…
-
In The NewsConfronting the next global health challengeNovartis Chairman Joerg Reinhardt says the successful fight against infectious diseases in poor countries provides valuable lessons for the emerging crisis of chronic diseases.
-
Media ReleaseNovartis führt "SMS for Life 2.0" in Nigeria ein, um den Zugang zu unentbehrlichen Arzneimitteln zu verbessern"SMS for Life 2.0" wird zum ersten Mal im Bundesstaat Kaduna, der bevölkerungsreichsten Region Nigerias, in Zusammenarbeit mit dem Gesundheitsministerium von Kaduna eingeführt. Das Programm nutzt…
-
Media ReleaseNovartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicinesSMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and…
-
Media ReleaseNovartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentielsSMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce…
-
Media ReleaseNovartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
-
Media ReleaseNovartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozoleMONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone …
-
Media ReleaseNovartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatmentUltibro® Breezhaler® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies Results further support the…
-
Media ReleaseNovartis' Lucentis® received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditionsThe European Commission approved Lucentis to treat patients for visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular…
-
Media ReleaseNovartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLCPatients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC[1] Patients with…
-
Featured NewsHealth experts explore response to chronic illness in poor countries
Health experts from around the world met November 29 to discuss ways to tackle an emerging crisis.
Pagination
- ‹ Previous page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- …
- 150
- › Next page